Therapy Areas: Cardiovascular
Eli Lilly and Company's orforglipron outperforms oral semaglutide in Phase 3 ACHIEVE-3 trial
17 September 2025 - Medicine firm Eli Lilly and Company (NYSE: LLY) on Wednesday reported positive topline results from ACHIEVE-3, a Phase 3, 52-week trial comparing the oral GLP-1 receptor agonist or...
Merck reports positive Phase 3 results for oral PCSK9 inhibitor enlicitide
2 September 2025 - US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, announced on Tuesday that its investigational oral PCSK9 inhibitor, enlicitide decan...
Abbott's Navitor TAVI system granted CE Mark for expanded indication
1 September 2025 - US-based medical device and healthcare company Abbott (NYSE:ABT) announced on Friday that it has received CE Mark in Europe for an expanded indication for its Navitor transcatheter ...
Cereno Scientific receives FDA Fast Track designation for CS1 in pulmonary arterial hypertension
26 August 2025 - Swedish drug development company Cereno Scientific AB (Nasdaq First North: CRNO B) announced on Tuesday that the US Food and Drug Administration has granted Fast Track designation to ...
FDA lifts clinical hold on Rocket Pharmaceuticals' RP-A501 Phase 2 Danon disease trial
20 August 2025 - Biotechnology company Rocket Pharmaceuticals Inc (NASDAQ: RCKT) announced on Wednesday that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its pivotal Pha...
OptiBiotix signs distribution deal with major weight management company
20 August 2025 - OptiBiotix Health plc (AIM: OPTI), a life sciences company specialising in microbiome-based health products, announced on Wednesday that it has signed a distribution agreement with a ...